Esperion Therapeutics: Strategically Positioned To Grow

Rasi Bhadramani Investment Thesis l am bullish on Esperion Therapeutios, Inc.(NASDAQ:ESPR) and rate it a buy given its strategic initiatives and markt pocential, which present an upbeat road map for sustain +52% Growth vs. 2Q23 $7.5 $33 528.3 2Q23 3Q23 4Q23 1Q24 2Q24 = U.S. Product Revenue ■ Royalty Revenue ESPR Q2 2024 Presentation These initiatives among other initiatives have seen the company register strong revenue growth and margin expansions particularly gross margins from Q4 2022 to Q2 2024 reported ...